comparemela.com
Home
Live Updates
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study ... : comparemela.com
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study ...
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant
Related Keywords
United States ,
Ukraine ,
American ,
Vikram Bali ,
American Heart Association ,
Exchange Commission ,
Bio Pharma Inc ,
Nasdaq ,
Drug Administration ,
European Society Of Cardiology Congress ,
Steering Committee ,
Twitter ,
Bridgebio Pharma Inc ,
Linkedin ,
Securities Exchange ,
University Of South Carolina ,
Win Ratio ,
Hazard Ratio ,
New Drug Application ,
Bio Pharma ,
Scientific Sessions ,
European Society ,
Cardiology Congress ,
Daniel Judge ,
Medical University ,
South Carolina ,
Bridgebio Pharma ,
Securities Act ,
Securities Exchange Act ,
Exchange Act ,
Risk Factors ,
Annual Report ,
Bio Media Contact ,
Nation World ,
Region ,
comparemela.com © 2020. All Rights Reserved.